The 13 members of the OxCD3 Steering Committee, listed below, are responsible for managing funding flexibility and reviewing funding allocation to Work Packages in light of recent clinical and industrial developments and the recommendations of the IAB.





Industrial member
Dr Pavel Novak
Storz



Industrial member
Dr Richard Green
Pfizer

EPSRC Representative
Dr Matthew Weaver

Industrial member
Dr Marianne Ashford
AstraZeneca

Industry member
Dr Christopher van der Walle
MedImmune